Safety and tolerability of donepezil in mild cognitive impairment: Open-label extension study

American Journal of Alzheimer's Disease and other Dementias

Volumn 25, Issue 2, 2010, Pages 155-159

  Doody, Rachelle S ^a   Ferris, Steven ^b,c   Salloway, Stephen ^d   Sun, Yijun ^e   Goldman, Robert ^f   Xu, Yikang ^f   Gao, Jeff ^e   Murthy, Anita K ^e  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d BROWN UNIVERSITY   (United States)

^e EISAI INC   (United States)

^f PFIZER INC   (United States)

Author keywords

Donepezil; Long term; Mild cognitive impairment; Safety

Indexed keywords

DONEPEZIL; PLACEBO;

ABNORMAL DREAMING; AGED; AMNESIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; URINARY TRACT INFECTION;

EID: 77749246004     PISSN: 15333175     EISSN: None     Source Type: Journal    
DOI: 10.1177/1533317509352334     Document Type: Article

References (14)

1. Petersen RC Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004 ; 256 (3). 183-194.
2. Petersen RC, Doody R., Kurz A., et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001 ; 58 (12). 1985-1992.
3. Morris JC, Storandt M., Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimergs disease. Arch Neurol. 2001 ; 58 (3). 397-405. (Pubitemid 32217456)
4. Park KW, Pavlik VN, Rountree SD, Darby EJ, Doody RS Is functional decline necessary for a diagnosis of Alzheimergs disease ? Dement Geriatr Cogn Disord. 2007 ; 24 (5). 375-379.
5. Feldman HH, Ferris S., Winblad B., et al. Effect of rivastigmine on delay to diagnosis of Alzheimergs disease from mild cognitive impairment: the InDDEx study. Lancet Neurol. 2007 ; 6 (6). 501-512.
6. Petersen RC, Thomas RG, Grundman M., et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. Alzheimergs Disease Cooperative Study Group. N Engl J Med. 2005 ; 352 (23). 2379-2388.
7. Salloway S., Ferris S., Kluger A., et al. Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial. Neurology. 2004 ; 63 (4). 651-657.
8. Winblad B., Gauthier S., Scinto L., et al. GAL-INT-11/18 Study Group. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology. 2008 ; 70 (22). 2024-2035.
9. Doody RS, Ferris SH, Salloway S., et al. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology. 2009 ; 72 (18). 1555-1561.
10. Raschetti R., Albanese E., Vanacore N., et al. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med. 2007 ; 4 (11). e388.
11. Birks J., Flicker L. Donepezil for mild cognitive impairment. Cochrane Database Syst Rev. 2006 ; 3: CD006104.
12. Feldman H., Gauthier S., Hecker J., et al. Donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimergs disease. Neurology. 2001 ; 57 (4). 613-620.
13. Winblad B., Engedal K., Soininen H., et al. Donepezil Nordic Study Group. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001 ; 57 (3). 489-495.
14. Razadyne [package insert]. Titusville, NJ: Ortho-McNeill Neuro-logics, Inc. ; 2007.